The 2-Minute Rule for ABBV-744 in the treatment of drug-resistant cancers
In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Members will acquire treatment right until ailment progression or perhaps the contributors are not able to tolerate the study drugs.Achievable new strategies with the prognosis and treatment of AML. (A) The identificatio